Once a product has been developed, we use robust scientific techniques to assess whether it reduces the risk of developing smoking-related disease.
Toxicity testing helps to predict whether a product will cause less damage in humans than cigarette smoke
We conduct two types of thorough toxicological assessment studies. The first is standard toxicology, where we use laboratory studies to assess whether the RRP vapors cause less damage to cells and organs than cigarette smoke. The second type is Systems Toxicology, where we use highly sophisticated laboratory techniques to assess the effect that the RRP vapors have on the development of smoking-related disease in comparison to cigarette smoke.
Systems toxicology helps us to understand the effects of switching to an RRP in a short timeframe
Most smoking related disease occur after decades of continued smoking. For example, Chronic Obstructive Pulmonary Disease (COPD) occurs after 25-30 years of regular smoking. Our cutting-edge systems toxicology techniques allow us to understand if switching to an RRP is likely to cause less smoking-related disease in a much shorter timeframe.
Toxicological assessment is used to complement our clinical studies
Toxicological assessment on its own does not prove if switching to an RRP is less harmful than continued cigarette use. That is determined by conducting clinical studies. However toxicological assessment does give us a very good indication and the confidence to move into thorough clinical trials in adult smokers.